PLRX Pliant Therapeutics Forecast, Technical & Fundamental Analysis
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies... Show more
PLRX is expected to report earnings to rise 7.25% to -34 cents per share on August 10
Q2'26
Est.
$-0.34
Q1'26
Beat
by $0.03
Q4'25
Beat
by $0.01
Q3'25
Beat
by $0.13
Q2'25
Missed
by $0.05
The last earnings report on May 11 showed earnings per share of -31 cents, beating the estimate of -35 cents. With 921.53K shares outstanding, the current market capitalization sits at 69.97M.
A.I. Advisor
published General Information
General Information
a company which engages in the business of developing and commercializing novel therapies for fibrotic diseases
A.I.dvisor indicates that over the last year, PLRX has been loosely correlated with LXRX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PLRX jumps, then LXRX could also see price increases.
The Moving Average Convergence Divergence (MACD) for PLRX turned positive on July 02, 2026. Looking at past instances where PLRX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PLRX advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 51 cases where PLRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on July 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PLRX as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for PLRX entered a downward trend on July 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PLRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.424) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). PLRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). PLRX's P/S Ratio (3333.333) is slightly higher than the industry average of (434.181).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PLRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
